Robert A. Michael - 15 Feb 2024 Form 4 Insider Report for AbbVie Inc. (ABBV)

Role: PRES & CHIEF OPERATING OFFICER
Signature: T.O. Odutayo, attorney-in-fact for Robert A. Michael
Issuer symbol: ABBV
Transactions as of: 15 Feb 2024
Net transaction value: $0
Form type: 4
Filing time: 20 Feb 2024, 17:15:14 UTC
Previous filing: 02 Mar 2023
Next filing: 01 Mar 2024
SEC filing: View on sec.gov

Key filing fact

Robert A. Michael filed Form 4 for AbbVie Inc. (ABBV) on 20 Feb 2024.

Key facts

This page summarizes Robert A. Michael's Form 4 filing for AbbVie Inc. (ABBV).
5 reported transactions and 1 derivative row are listed below.
Filing timestamp: 20 Feb 2024, 17:15.

Change

Previous filing in this sequence was filed on 02 Mar 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

See Original Filing

Reported transactions

ABBV transaction

Common Stock, $0.01 par value

Award

Transaction value: $0
Shares: +49,565
Change %: +50%
Price: $0.000000
Shares after: 148,210
Date: 15 Feb 2024
Ownership: Direct
Footnotes: F1

ABBV transaction

Common Stock, $0.01 par value

Award

Transaction value: $0
Shares: +13,216
Change %: +8.9%
Price: $0.000000
Shares after: 161,426
Date: 15 Feb 2024
Ownership: Direct
Footnotes: F2

ABBV transaction

Common Stock, $0.01 par value

Award

Transaction value: $0
Shares: +10,146
Change %: +6.3%
Price: $0.000000
Shares after: 171,572
Date: 15 Feb 2024
Ownership: Direct
Footnotes: F3

ABBV transaction

Common Stock, $0.01 par value

Award

Transaction value: $0
Shares: +12,030
Change %: +7%
Price: $0.000000
Shares after: 183,602
Date: 15 Feb 2024
Ownership: Direct
Footnotes: F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

ABBV transaction Derivative

Option (Right to Buy)

Award

Transaction value: $0
Shares: +59,888
Change %
Price: $0.000000
Shares after: 59,888
Date: 15 Feb 2024
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 59,888
Exercise price: $0.000000
Footnotes: F5

^* indicates a reported price that failed the local validity check.

Explanation of Responses:

Id	Content
F1	Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 18, 2021. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2024.
F2	Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 18, 2021. The award is subject to performance-vesting restrictions based on a relative return on invested capital measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2024.
F3	Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 17, 2022. The award is subject to performance-vesting restrictions based on a relative return on invested capital measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2024.
F4	Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 16, 2023. The award is subject to performance-vesting restrictions based on a relative return on invested capital measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2024.
F5	Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 19,963 on February 15, 2025, 19,963 on February 15, 2026, and 19,962 on February 15, 2027.